Formulation to improve survival of transplanted cells

Details Formulation to improve survival of transplanted cells Formulation to improve survival of transplanted cells

2011-01-25

2011-01-25

Davis, Ruth A (Department: 1651)

Chemistry: molecular biology and microbiology

Animal cell, per se ; composition thereof; process of...

Reexamination Certificate

active

07875451

ABSTRACT:
The survival of cells during transplantation is enhanced. Cells to be transplanted are administered in a formulation that provides two ore more survival enhancing factors. Optionally, prior to administration, the cells are cultured in the presence of factors that enhance survival, and may be heat shocked prior to transplantation.

REFERENCES:
patent: 5354764 (1994-10-01), Grover et al.
patent: 6437097 (2002-08-01), Hsueh et al.
patent: 2001/0053354 (2001-12-01), Dinsmore
patent: 2005/0054092 (2005-03-01), Xu et al.
patent: 2005/0058630 (2005-03-01), Harris et al.
Suzuki et al., Circulation, 2000, 102, suppl III:III-216-221.
Contreras, J., et al, “Cytoprotection of pancreatic islets before and early after transplantation using gene therapy,” (2002)Kidney International, 61(Symposium 1):S-79—S-84.
Fearnhead, H,, et al., “A pre-existing protease is a common effector of thymocyte apoptosis mediated by diverse stimuli,” (1995)FEBS Letters, 357:242-246.
He, J., et al., “Human embryonic stem cells develop into multiple types of cardiac myocytes: action potential characterization,” (2003)Circulation Research, 93:32-39.
Jackson, K., et al., “Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells,” (2001)The Journal of Clinical Investigation, 107(11):1395-1402.
Kehat, I., et al., “Human embryonic stem cells can differentiate into myocytes with structural and functional properties of cardiomyocytes,” (2001) 108(3):407-414.
Kleinman, H., et al., “Matrigel: Basement membrane matrix with biological activity,” (2005)Elsevier Seminars in Cancer Biology, 15:378-386.
Laflamme, M., et al., “Formation of human myocardium in the rat heart from human embryonic stem cells,” (2005)American Journal of Pathology, 167(3):663-671.
Malhotra, R., et al., “Glucose uptake and glycolysis reduce hypoxia-induced apoptosis in cultured neonatal rat cardiac myocytes,” (1999)The Journal of Biological Chemistry, 274(18)12567-12575.
Mehrhof, F., et al., “In cardiomyocyte hypoxia, insulin-like growth factor-l-induced antiapoptotic signaling requires phosphatidylinositol-3-OH-kinase-dependent and mitogen-activated protein kinase-dependent activation of the transcription factor cAMP response element-binding protein,” (2001)Circulation104:2088-2094.
Mummery, C., et al., “Cardiomyocyte differentiation of mouse and human embryonic stem cells,” (2002)Journal of Anatomy200:233-242.
Mummery, C., et al., “Differentiation of human embryonic stem cells to cardiomyocytes: role of coculture with visceral endoderm-like cells,” (2003)Circulation107:2733-2740.
Oh, H., et al., “Cardiac progenitor cells from adult myocardium: homing, differentiation, and fusion after infarction,” (2003)PNAS, 100(21)12313-12318.
Reinecke, H., et al., “Electromechanical coupling between skeletal and cardiac muscle: implications for infarct repair,” 149(3):731-740.
Reinecke, H., et al., “Skeletal muscle stem cells do not transdifferentiate into cardiomyocytes after cardiac grafting,” (2002)Journal of Molecular Cell Cardiology34:241-249.
Reiss, K., et al., “Insulin-like growth factor-1 receptor and its ligand regulate the reentry of adult ventricular myocytes into the cell cycle,” (1997)Experimental Cell Research, 235:198-209.
Schierle, G., et al., “Caspase inhibition reduces apoptosis and increases survival of nigral transplants,” (1999)Nature Medicine5(1):97-100.
Shim, et al., “Stem cell cardiomyoplasty: state-of-the-art,” (2004)Annals Academy of Medicine Singapore, 33(4):451-460.
Shimizu, S., et al., “BH4 domain of antiapoptotic BcI-2 family members closes voltage-dependent anion channel and inhibits apoptotic mitochondrial changes and cell death,” (2000)PNAS, 97(7):3100-3105.
Skuk, D., et al., “Resetting the problem of cell death following muscle-derived cell transplantation: detection, dynamics and mechanisms,” (2003)Journal of Neuropathology and Experimental Neurology, 62(9):951-967.
Szmitko, P., et al., “Endothelial Progenitor Cells,” (2003)Circulation, 107:3093-3100.
Tomita, S., et al., “Autologous transplantation of bone marrow cells improves damaged heart function,” (1999)Circulation, 100:II-247—II-256.
Vanden Hoek, T., et al., “Preconditioning in cardiomyocytes protects by attenuating oxidant stress at reperfusion,” (2000)Circulation Research, 2000(86):541-548.
Zandstra, P.W., et al., “Scalable production of embryonic stem cell-derived cardiomyocytes,” (2003)Tissue Engineering, 9(4):767-778.
Zhang, M., et al., “Cardiomyocyte grafting for cardiac repair: graft cell death and anti-death strategies,” (2001)Journal of Molecular Cell Cardiology, 33:907-921.
Zimmerman, W., et al., “Cardiac grafting of engineered heart tissue in syngenic rats,” (2002)Circulation, 106(Suppl I):I-151—I-157.

Affiliated with

Also associated with

Rating

Formulation to improve survival of transplanted cells does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Formulation to improve survival of transplanted cells, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Formulation to improve survival of transplanted cells will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2644178